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Background: Interest in Equine Gastric Ulcer Syndrome (EGUS) has recently increased in part due to a growing
awareness of the differences between squamous and glandular disease. The pathophysiology and epidemiology of
squamous and glandular disease are different and recently it has been shown that the response of glandular gastric
ulceration to monotherapy with omeprazole is poor. Given these differences it has been recommended that specific
treatment guidelines be formulated for equine glandular disease and that adjunctive therapies be investigated. Along
these lines it has been suggested that the addition of antimicrobials may enhance healing. The objective of this study
was to investigate whether the addition of trimethoprim-sulphadimidine to omeprazole therapy would result in
superior healing of naturally occurring equine glandular ulceration compared with omeprazole monotherapy.
Results: Combination therapy of omeprazole plus trimethoprim-sulphadimidine could not be demonstrated to
be superior to omeprazole monotherapy. Healing of the glandular mucosa was observed in 7/15 (47%; 95% CI
24 to 71%) and 3/13 (23%; 95% CI 7% to 50%) of horses in the TMPS and OMEP groups, respectively (OR = 1.8;
95% CI 0.32 to 10.0; p = 0.67). Improvement of the glandular mucosa was observed in 12/15 (80%; 95% CI 56 to
94%) and 9/13 (69%; 95% CI 42 to 89%) of horses in the TMPS and OMEP groups, respectively (OR = 2.9; 95% CI
0.6 to 15.0; p = 0.25).
Conclusions: The results of the present study do not support the addition of trimethoprim-sulphadimidine to
therapeutic protocols for equine glandular ulceration. Several limitations were present in the study and the use
of antimicrobials as an adjunctive treatment warrants further investigation. However, given the potential deleterious
consequences associated with the indiscriminate use of antimicrobials, the inclusion of antimicrobials in treatment
regimes for EGUS is not justified until their efficacy is further validated.
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The term Equine Gastric Ulcer Syndrome (EGUS) is
widely used to describe gastric ulceration in the horse.
However, by definition the term EGUS refers to a syn-
drome, within which numerous disease entities exist.
Distinction between diseases of the squamous and glan-
dular mucosa is important with each having a different* Correspondence: gaylehallowell@yahoo.co.uk
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unless otherwise stated.proposed pathophysiology and risk factors [1-4]. Fur-
thermore, it has been reported that the presence of
squamous and glandular ulceration within an individual
are unrelated [5-7] and the response of glandular ulcer-
ation to monotherapy with omeprazole appears inferior
to that of squamous ulceration. In three recent studies
only 25% of glandular ulcers healed with 28-35 days of
omeprazole therapy at 4.0 mg/kg PO SID in direct con-
trast to a squamous healing rate of 78% [8-10]. Together
the results of these studies clearly demonstrate that the ex-
trapolation of treatment recommendations from squamoustd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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and that specific guidelines are needed for the treatment of
glandular gastric ulceration in the horse.
In humans, therapeutic protocols for glandular ulcer-
ation are dictated by the underlying disease process with
Helicobacter pylori-associated ulcers treated with short
duration (7 – 14 days) triple therapy combining antimi-
crobials and acid suppression in a variety of protocols
[11]. In contrast, NSAID-induced glandular ulceration is
typically treated for 8-12 weeks with acid suppression
therapy alone [12]. As of yet the pathogenesis of equine
glandular ulceration is undetermined and, as such, the
formulation of specific treatment recommendations based
on the underlying disease process is difficult. There re-
mains significant conflict in the literature as to the role of
bacteria in EGUS with Helicobacter-like organisms identi-
fied in affected horses in some studies [13-15], whilst
other studies have failed to identify such organisms.
[16,17]. A recent study demonstrated that both gastric-
adapted bacteria and opportunistic pathogens may play
a role in squamous ulceration [18] and, although proof
is lacking, it is suspected that bacteria may play a role
in the either the development or perpetuation of equine
glandular ulceration. In line with this, it has been sug-
gested that antimicrobial therapy may be beneficial in
treatment [19,20].
Based on this the authors hypothesized that the combin-
ation of omeprazole at 4 mg/kg PO SID and trimethoprim-
sulphadimidine (TMPS) at a dose of 30 mg/kg PO SID
would improve outcome over monotherapy with omepra-




The study was performed in accordance with the New
South Wales Department of Primary Industries guide-
lines for clinical studies and the New South Wales Ani-
mal Research Act of 1985. Informed consent from the
owner, or the trainer acting as an agent for the owner,
was obtained at the time of enrolment to the study.
Study design
A randomised, blinded, clinical study.
Recruitment and examination
Thoroughbred horses from 5 different stables were ex-
amined during July 2012. Prior to examination all horses
were fed their normal evening feed, but any remaining
food was removed 6 – 8 hours prior to endoscopy.
Water was not withheld and horses were exercised nor-
mally on the morning of the examination at the trainers’
discretion.Horses were sedated with detomidine (10-20 μg/kg
bwt IV)a and examined for the presence of gastric ulcer-
ation using a 3 meter flexible gastroscopeb. The squa-
mous and glandular mucosa were scored separately
using a 4 point scale as described by the EGUS council
[21]. Based on the results of the gastroscopic examin-
ation, horses that met the inclusion criteria were en-
rolled into the study. Inclusion criteria for the study
were horses with grade 2 or greater ulceration of the
glandular mucosa, in race training and expected to re-
main in work for the next 4 weeks, not receiving any
other medical treatment for EGUS and otherwise con-
sidered to be free of other significant disease.
Group allocation and blinding
Once enrolled into the study, horses were stratified by their
existing trainer to reduce variability in the diet and manage-
ment as these have been shown to be significant risk factors
for glandular ulcer development [4]. Horses were then ran-
domly allocated to receive either omeprazole alone (group
OMEP) or omeprazole plus trimethoprim-sulphadimine
(group TMPS) by pulling their names out of a hat. One in-
vestigator (KS) was responsible for randomization whilst the
remaining investigators, including the principal investigator
(BS) who undertook the gastroscopic examinations and
scoring, remained blinded to the group allocation until scor-
ing was completed and recorded. The trainers were not
blinded to treatment group. The study protocol allowed for
randomization to be broken in the event of an adverse
event.
Treatment protocols
Horses were fed and exercised at the trainers’ discretion
driven by their normal routine, housed in individual
stalls, bedded on wood shavings and fed a diet typical of
Australian racehorses [22]. All horses were fed twice
daily, with the morning feed typically within 2 hours of
completing exercise, and the afternoon feed approxi-
mately 12-14 hours before exercising. All horses received
2 grams, equivalent to 4 mg/kg for a 500 kg horse, of a
commercially available, enteric coated omeprazole paste
formulationc PO 1 – 4 hours prior to morning exercise.
At the same time, horses in group TMPS also received
15 grams, equivalent to a combined trimethoprim-
sulphadimined dose of 30 mg/kg for a 500 kg horse, of
a commercially available oral trimethoprim-sulfadimidine
pasteg PO. To comply with the local regulations for
racing, omeprazole was not administered on the day of
racing.
Follow up endoscopy
Repeat gastroscopy, as described above, was scheduled
between days 21 and 28. Some variation was allowed in
the timing of the repeat gastroscopic examination to
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The squamous and glandular mucosa was scored and
assessed separately for each horse. Where the starting
grade was ≥ 2 for the particular mucosa, ulcer healing was
defined as change to a grade of 0-1 as previously described
[10]. Where a starting ulcer grade of ≥ 2 was present in
the particular mucosa, horses were considered to have im-
proved if the ulcer score for the region decreased by at
least one grade. As previously described [23], where the
starting score, for either the squamous or glandular mu-
cosa, was ≥ 2 and subsequently changed to 0-1 the horse
was considered to have both healed and improved for that
mucosa as the definition of both improvement and heal-
ing had been met. Horses with a sub-maximal starting
ulcer grade (<4) for the squamous or glandular mucosa
were considered to have worsened if their ulcer grade for
that particular mucosa increased by at least one grade.
Statistical analysis
As no data was available at the time of the study on the
expected degree of healing of glandular ulceration with
either omeprazole alone of the combination of omepra-
zole plus trimethoprim-sulfadimidine a power calculation
was not performed. Instead the horses were enrolled on
the basis of their availability.
Data was assessed for normality using D’Agostino and
Pearson omnibus normality test. Data for age, weight
and time between gastroscopic examinations in the 2
groups were normally distributed and 2-tailed unpaired
Student T-tests were used to assess differences between
the groups. All other data was not normally distributed.
Genders between the two groups were compared using a
two-sided Fisher’s exact test. Baseline data for squamous
and glandular ulcer scores were compared using a Mann
Whitney U test. A Wilcoxon Paired Test was used to as-
sess changes in ulcer scores within groups over time. A
Mann Whitney U test was used to compare squamous
and glandular ulcer scores overall and between the two
groups. A Chi-squared analysis or Fisher’s exact test
(if >25% of entries had a frequency of 5 or less) were
used to assess improvement or healing of ulcers.
Three commercially available statistical software pack-
ages were usede-g. The remaining 95% confidence inter-
vals displayed use Jeffrey’s intervals and were calculated
using online statistical softwareg. Data is presented as
mean ± SD if normally distributed and median and inter-
quartile ranges (IQR) if not normally distributed. Odds
ratios and 95% confidence intervals are displayed for bi-
nomial data. Significance was determined when p < 0.05.
Results
Horses
Twenty-nine horses (16 geldings and 13 females) aged
from 2 to 7 years met the inclusion criteria and wererandomly allocated into two groups with 15 horses in
group TMPS and 14 horses in group OMEP. No adverse
events were noted and blinding was maintained through-
out the study with the exception of the one horse from
group OMEP that was diagnosed with a lower respiratory
tract infection during week 2 of the study. To ensure ap-
propriate treatment, randomization for this horse was
broken and it was subsequently excluded from data ana-
lysis leaving 13 horses in group OMEP. No other horse re-
ceived antimicrobials in the study period.
Mean weight for the TMPS and OMEP treatment
groups was 503 ± 27 kg and 510 ± 23 kg, respectively
and not different between groups (p = 0.52). There was
no difference in baseline data between groups at enrol-
ment for age (p = 0.12), and gender (TMPS – 7 females
and 8 males; OMEP - 5 females and 8 males; p = 0.66).
Days to follow-up and number of race starts
The number of days to follow-up examination was not
different between the two groups (24.5 ± 2.3 and 25.1 ±
1.9 in group TMPS and OMEP, respectively; p = 0.51).
There was no difference in the number of race starts be-
tween groups (median 2 (IQR: 0-2) and median 2 (IQR:
0-2) in group TMPS and OMEP, respectively; p = 0.61).
Ulcer scores
The entire squamous mucosa was adequately observed
in all examinations. Residual fluid in the stomach pre-
vented observation of the most ventral portion of the
glandular body; however the entire pyloric antrum was
visible in all examinations. There was no difference be-
tween median squamous ulcer scores when the two
treatment groups were compared (TMPS – 2 (IQR: 1-2)
to 0 (IQR: 0-0; p = 0.06) and OMEP – 2 (IQR: 1-2) to 0
(IQR: 0-1; p = 0.06)) over time. As the primary purpose
of the study was to assess healing of glandular ulcers, no
further analysis of squamous healing or improvement
was performed.
There was no difference between groups regarding
glandular ulcer score at enrolment (p = 0.72). Glandular
ulcer scores significantly decreased in both treatment
groups (TMPS – p = 0.0005 and OMEP – p = 0.004) over
time (Figure 1). There was no difference between the
treatment groups regarding change in glandular ulcer
score over time (p = 0.27). Improvement of the glandular
mucosa was observed in 12/15 (80%; 95% CI 56 to 94%)
and 9/13 (69%; 95% CI 42 to 89%) of horses in the
TMPS and OMEP groups, respectively (OR = 1.8; 95%
CI 0.32 to 10.0; p = 0.67). Healing of the glandular mu-
cosa was observed in 7/15 (47%; 95% CI 24 to 71%) and
3/13 (23%; 95% CI 7 to 50%) of horses in the TMPS and
OMEP groups, respectively (OR = 2.9; 95% CI 0.6 to
15.0; p = 0.25). Worsening of glandular ulcer grade was
not observed.
Figure 1 Box and whisker plot demonstrating median (solid
line), inter-quartile ranges (represented by outer edges of box)
and ranges (error bars) before and after treatment for glandular
ulcer grades for horses treated with omeprazole at 4 mg/kg PO
SID (n = 13) or omeprazole at 4 mg/kg PO SID plus trimethoprim-
sulphadimidine (TMPS) at 30 mg/kg PO SID (n = 15). There was no
difference between the treatment groups regarding change in
glandular ulcer score over time (p = 0.27).
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The results of the present study suggest that the
addition of trimethoprim-sulphadimidine (TMPS) at 30
mg/kg PO SID does not improve the response of equine
glandular ulceration compared with omeprazole mono-
therapy. As such the results do not support the addition
of TMPS to therapeutic protocols for the treatment of
glandular gastric ulceration in the horse.
Several possible reasons, beyond a true lack of efficacy,
for the failure of TMPS to improve healing in this study,
including the antimicrobial used, the dose given and the
duration of therapy, have been identified by the authors
and warrant discussion. The use of specific, targeted
antimicrobial therapy is not possible in the horse due to
the failure, thus far, to identify a specific pathogen in the
pathogenesis of equine glandular ulceration. This is in
contrast with glandular ulceration in humans where,
when the organism is identified, antimicrobial selection
is primarily targeted at H. pylori [11]. The choice of
TMPS in this study was based on a its broad spectrum
of activity, good penetration [24] and the high likelihood
that, given its ease of use, availability and affordability, it
would be selected as a first choice antimicrobial under
clinical situations. Healing of squamous ulceration has
been observed with 28 days of treatment of TMPS, with-
out acid suppression therapy [18], further supporting the
selection of TMPS. Whether a similar result would be
observed with a different antimicrobial, or multiple con-
current antimicrobials as used in humans, is unknown
but warrants investigation. However, making an evidence
guided choice of such an antimicrobial is difficult and a
further understanding of the role of bacteria, and the
identification of specific species that may be involved in
the pathogenesis of equine glandular ulceration, wouldbe advantageous in the selection of an antimicrobial, or
antimicrobials, for future trials.
An alternative explanation for the failure to see an ef-
fect of the addition of TMPS is that the dose used in the
present study was too low. A range of dose recommen-
dations, from a total daily dose of 30 - 60 mg/kg, exists
for the oral administration of TMPS [25]. The dose se-
lected in this study based primarily on four factors;
firstly, it is the registered dose for the formulation used;
secondly in the aforementioned study, in which squa-
mous healing was observed with TMPS monotherapy,
the total daily dose was 30 mg/kg PO [18] suggesting
that an effect on gastric ulceration can be observed at
the lower end of the dose range; thirdly, it has been sug-
gested that tissue concentrations may more accurately
reflect the efficacy of antimicrobials than plasma con-
centrations and tissue chamber fluids of both trimetho-
prim and sulphadiazine remain above MIC for at least
24 hours following the administration of 30 mg/kg PO
in fed ponies [24]; and lastly, fasting improves the bio-
availability of trimethoprim-sulphachlorpyridazine by ap-
proximately 50% [26]. Although the horses in this study
were not specifically fasted, the authors have observed
that the majority of animals consume their meals within
4 hours resulting in an effective fasting period of around
8 -10 hours each day prior to administration of the med-
ications the following morning. The authors propose
that it is likely that this would have resulted in greater
bioavailability of TMPS potentially further enhancing tis-
sue concentrations above that seen in fed animals. Tak-
ing the reported tissue concentrations and the possible
effect of a brief fast on absorption together, the authors
consider that it is likely that tissues concentrations were
maintained above MIC with the dose used.
The last potential explanation for the failure of TMPS
to improve healing is that the duration of therapy may
have been inadequate for an effect to be seen. In humans
with H. pylori associated ulcers, triple therapy combin-
ing antimicrobials and acid suppression consistently
yields first line eradication rates of greater than 80% with
7 – 14 days of therapy [11]. As such, the authors con-
sider it unlikely that a longer duration of therapy would
have resulted in a different outcome.
In the absence of an effect of the above factors the re-
sults of this study suggest that TMPS does not enhance
healing of equine glandular ulceration. The first limita-
tion of the study was the small number of animals stud-
ied and the risk of a type II error wherein an effect was
present but not demonstrated should be considered
when interpreting the results of the study. The raw data
suggests that an effect may be present while the wide
confidence intervals suggest that the point estimates of
efficacy are likely to be imprecise and that the risk of a
type II error is high. Considering this, the authors
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tion whether a higher dose of TMPS (30 mg/kg PO
BID), or the use of an alternative antimicrobial, would
have resulted in superior healing. However, given the po-
tential deleterious consequences associated with the in-
discriminate use of antimicrobials, the authors argue
that the widespread usage of antimicrobials in the treat-
ment of EGUS should be discouraged until studies into
the efficacy of antimicrobials document a positive effect.
The second limitation of the study was that samples for
bacterial culture and histopathology were not obtained
from the gastric mucosa and should certainly be under-
taken were this study carried out in a larger population.Conclusions
The results of this study do not support the addition of
TMPS to therapeutic protocols for equine glandular ul-
ceration. Whether the use of different antimicrobials, or
a higher dose of TMPS, would result in enhanced heal-
ing is not clear but warrants investigation. However,
based on the present study, the inclusion of antimicrobials
in treatment regimes for equine glandular ulceration is
not justified until their efficacy is further validated.Manufacturers addresses
aDozadine, Axon Animal Health, Belrose, NSW, Australia;
bPortascope, Portascope.com, Bradenton, Florida, USA;
cGastrozol, Axon Animal Health, Belrose, NSW, Australia;
dIlium Sulprim, Troy Laboratories, Glendenning, NSW,
Australia; eGraphPad 6.0, Graphpad Software, La Jolla,
California, USA; fSPSS for Windows 21.0, SPSS Inc,
Chicago, Illinois, USA; ghttp://epitools.ausvet.com.au/
content.php?page=CIProportion; hWinpepi Compare 2
3.08. www.brixtonhealth.com/pepi4windows.html
Competing interests
None of the author’s received payment for performing the study, nor do any
have relationships, financial or otherwise, that could reasonably be expected
to influence the outcome of the study.
Authors’ contributions
BS designed the study, performed the gastroscopic examinations, collated
the data and drafted the manuscript. KS contributed to the execution of the
study. GH contributed to the study design and performed the statistical
analysis. All authors have read and approved the manuscript.
Acknowledgment
The authors would like to thank Axon Animal Health and Portascope.com for
their generous support of the project. This study was funded by Axon
Animal Health through the provision of the medications used. Portoscope.
com supported the study through the provision of a gastroscope for
research purposes. We would also like to thank the trainers for their co-operation
and Ashleigh Dand and Arja Pöntinen for their assistance in performing the
examinations.
Author details
1BW Sykes Consultancy, Upper Orara, NSW, Australia. 2School of Veterinary
Medicine and Science, University of Nottingham, Sutton Bonington, UK.Received: 20 March 2014 Accepted: 6 August 2014
Published: 23 August 2014
References
1. Dionne R, Vrins A, Doucet M: Gastric ulcers in Standardbred racehorses:
prevalence, lesion description, and risk factors. J Vet Int Med 2003,
17:218–222.
2. Luthersson N, Nielsen KH, Harris P, Parkin TDH: Risk factors associated with
equine gastric ulceration syndrome (EGUS) in 201 horses in Denmark.
Equine Vet J 2009, 41:625–630.
3. McClure S, Carithers D, Gross S: Gastric ulcer development in horses in a
simulated show or training environment. J Am Vet Med Ass 2005,
227:775–777.
4. Habershon-Butcher JL, Hallowell GD, Bowen IM, Sykes BW: Prevalence and
risk factors for ulceration of the gastric glandular mucosa in
Thoroughbred racehorses in training in the UK and Australia [abstract].
J Vet Int Med 2012, 26:731.
5. Begg LM, O’Sullivan CB: The prevalence and distribution of gastric
ulceration in 345 racehorses. Aust Vet J 2003, 81:199–201.
6. Luthersson N, Nielsen KH, Harris P, Parkin TDH: The prevalence and
anatomical distribution of equine gastric ulceration syndrome (EGUS) in
201 horses in Denmark. Equine Vet J 2009, 41:619–624.
7. Murray MJ, Nout YS, Ward DL: Endoscopic findings of the gastric antrum and
pylorus in horses: 162 cases (1996-2000). J Vet Int Med 2001, 15:401–406.
8. Sykes BW, Sykes KM, Hallowell GD: A comparison of three doses of
omeprazole in the treatment of gastric ulceration in the horse: a
randomised, blinded clinical trial [abstract]. J Vet Int Med 2013, 27:652.
9. Sykes BW, Sykes KM, Hallowell GD: A comparison between pre- and
post-exercise administration of omeprazole in the treatment of EGUS:
a randomised, blinded clinical trial. Equine Vet J 2013, Early View:1–5.
10. Sykes BW, Sykes KM, Hallowell GD: A comparison of two doses of
omeprazole in the treatment of EGUS: a blinded, randomised, clinical
trial. Equine Vet J 2013, Early View:1–6.
11. Malfertheiner P, Chan FFKL, McColl KEL, Leung W: Peptic-ulcer disease.
Lancet 2009, 374:1449–1461.
12. Goldstein JL, Johanson JF, Hawkey CJ, Suchower LJ, Brown KA: Clinical trial:
healing of NSAID-associated gastric ulcers in patients continuing NSAID
therapy - a randomized study comparing ranitidine with esomeprazole.
Aliment Pharmacol Ther 2007, 26:1101–11.
13. Contreras M, Morales A, García-Amado MA, De Vera M, Bermúdez V,
Gueneau P: Detection of Helicobacter-like DNA in the gastric mucosa of
Thoroughbred horses. Lett Appl Microbiol 2007, 45:553–557.
14. Morales A, Garcia F, Bermudez V: Detection of Helicobacter-like organisms
in Thoroughbred horses from Venezuela. Braz J Vet Path 2010, 3:52–55.
15. Fox J: The non-H pylori helicobacters: their expanding role in gastrointestinal
and systemic diseases. Gut 2002, 50:273–283.
16. Husted L, Jensen TK, Olsen SN, Mølbak L: Examination of equine glandular
stomach lesions for bacteria, including Helicobacter spp by fluorescence
in situ hybridisation. BMC Microbiol 2010, 10:1–8.
17. Martineau H, Thomson H, Taylor D: Pathology of gastritis and gastric
ulceration in the horse. Part 1: range of lesions present in 21 mature
individuals. Equine Vet J 2009, 41:638–644.
18. Al Jassim R, McGowan T, Andrews F, McGowan C: Gastric Ulceration In
Horses: The Role Of Bacteria And Lactic Acid. In Australian Government:
Rural Industries Research and Development Corporation; 2008:1–26.
19. Hepburn R: Gastric ulceration in horses. In Pract 2011, 33:116–124.
20. Nadeau JA, Andrews FM: Equine gastric ulcer syndrome: the continuing
conundrum. Equine Vet J 2009, 41:611–615.
21. Andrews F, Bernard W, Byars D, Cohen N, Divers T, MacAllister C,
McGladdery A, Merritt A, Murray M, Orsini J, Snyder J, Vatistas N:
Recommendations for the diagnosis and treatment of equine gastric
ulcer syndrome (EGUS). Equine Vet Educ 1999, 11:262–272.
22. Richards N, Hinch GN, Rowe JB: The effect of current grain feeding
practices on hindgut starch fermentation and acidosis in the Australian
racing Thoroughbred. Aust Vet J 2006, 84:402–407.
23. Andrews FM, Sifferman RL, Bernard W, Hughes FE, Holste JE, Daurio CP,
Alva R, Cox JL: Efficacy of omeprazole paste in the treatment and
prevention of gastric ulcers in horses. Equine Vet J, Suppl 1999, 31:81–86.
24. Van Duijkeren E, Ensink JM, Meijer LA: Distribution of orally administered
trimethoprim and sulfadiazine into noninfected subcutaneous tissue
chambers in adult ponies. J Vet Pharm Ther 2002, 25:273–7.
Sykes et al. BMC Veterinary Research 2014, 10:180 Page 6 of 6
http://www.biomedcentral.com/1746-6148/10/18025. Robinson NE: Current Therapy in Equine Medicine (5th Ed). 5th edition.
Edited by Robinson NE. Elseveir; 2003:859–869.
26. Van Duijkeren E, Vulto AG, van Oldruitenborgh-Oosterbaan MM S, Kessels BG, Van
Miert AS, Breukink HJ: Pharmacokinetics of trimethoprim/sulphachlorpyridazine
in horses after oral, nasogastric and intravenous administration. J Vet
Pharm Ther 1995, 18:47–53.
doi:10.1186/s12917-014-0180-0
Cite this article as: Sykes et al.: Administration of
trimethoprim-sulphadimidine does not improve healing of glandular gastric
ulceration in horses receiving omeprazole: a randomised, blinded, clinical
study. BMC Veterinary Research 2014 10:180.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
